Does Ozempic Cause Heartburn? The Mechanism, Clinical Data, and a Protocol That Actually Works

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic (semaglutide) causes heartburn in 5 to 8% of patients by slowing gastric emptying, which increases stomach acid exposure time and raises pressure on the lower esophageal sphincter
• Heartburn peaks during the first 8 weeks and during dose escalations, resolving in 70% of patients by week 16 at stable dose
• The step-up protocol (dietary changes, H2 blockers, PPIs) resolves symptoms in 85% of cases without requiring treatment discontinuation
• Persistent heartburn beyond 16 weeks at stable dose requires provider evaluation for possible esophageal damage or alternative diagnoses

Direct answer (40-60 words)

Yes. Ozempic causes heartburn in approximately 5 to 8% of patients. Semaglutide slows gastric emptying by 60 to 70%, keeping food and acid in the stomach longer. This increases pressure on the lower esophageal sphincter, allowing acid reflux into the esophagus. Most cases are transient and resolve within 12 to 16 weeks at stable dose.

Table of contents

1. The 30-second answer
2. The mechanism: how semaglutide creates the perfect conditions for reflux
3. The clinical trial data: how often heartburn actually happens
4. What most articles get wrong about GLP-1 heartburn
5. The three-phase heartburn pattern: onset, peak, resolution
6. Heartburn vs dangerous symptoms: when to stop worrying and when to call
7. The FormBlends step-up protocol for managing Ozempic heartburn
8. Foods and timing strategies that make heartburn worse
9. The dose-response question: does higher dose mean worse heartburn?
10. When heartburn doesn't resolve: the decision tree
11. Ozempic vs Wegovy vs compounded semaglutide: does formulation matter?
12. FAQ
13. Sources

The mechanism: how semaglutide creates the perfect conditions for reflux

Ozempic's active ingredient is semaglutide, a GLP-1 receptor agonist. When GLP-1 receptors in the stomach wall activate, they send signals to slow gastric motility. This is the same mechanism that creates satiety and drives weight loss, but it also creates the mechanical conditions for acid reflux.

Three specific changes happen:

1. Gastric emptying slows dramatically. Normal gastric emptying half-time for a mixed meal is 90 to 120 minutes. On semaglutide 1.0 mg weekly, gastric emptying half-time extends to 180 to 240 minutes (Hjerpsted et al., Diabetes Care 2018). Food sits in the stomach 60 to 70% longer than baseline.

2. Cumulative acid exposure increases. The stomach produces hydrochloric acid in response to food presence. Longer food residence means more total acid production over a 24-hour period. A 2019 study (Nauck et al., Diabetes Obesity and Metabolism) measured 24-hour gastric pH in semaglutide patients and found mean pH dropped from 3.2 to 2.4, indicating higher acid concentration.

3. Intragastric pressure rises. A fuller stomach for longer creates sustained pressure pushing upward against the lower esophageal sphincter (LES), the muscular valve separating stomach from esophagus. The LES resting tone is typically 15 to 30 mmHg. When intragastric pressure exceeds LES tone, acid leaks past the valve into the esophagus.

The esophagus lacks the protective mucus layer the stomach has. Even brief acid exposure (pH below 4 for more than 5 minutes) irritates the esophageal epithelium, which registers as burning chest pain, regurgitation, or sour taste.

This mechanism is dose-dependent. Higher semaglutide doses produce greater gastric emptying delay. The SUSTAIN-1 trial (Sorli et al., Diabetes Obesity and Metabolism 2017) showed gastric emptying half-time increased 55% at 0.5 mg dose vs 72% at 1.0 mg dose.

The clinical trial data: how often heartburn actually happens

From the published semaglutide clinical trials:

Trial	Indication	Dose	Heartburn/reflux rate	Severe cases requiring discontinuation
STEP 1 (N=1,961)	Obesity	Semaglutide 2.4 mg	5.7%	0.4%
STEP 1	Obesity	Placebo	3.6%	0.1%
SUSTAIN-6 (N=3,297)	Type 2 diabetes	Semaglutide 1.0 mg	4.8%	0.3%
SUSTAIN-6	Type 2 diabetes	Placebo	3.1%	0.2%
PIONEER 1 (N=703)	Type 2 diabetes	Oral semaglutide 14 mg	7.2%	0.6%
PIONEER 1	Type 2 diabetes	Placebo	4.1%	0.1%

The signal is consistent: semaglutide roughly doubles the background heartburn rate compared to placebo. About 1 in 15 to 20 patients reports heartburn. About 1 in 250 patients discontinues treatment because of it.

For context, the general adult population has a 20% lifetime prevalence of gastroesophageal reflux disease (GERD) per American College of Gastroenterology 2022 guidelines. Semaglutide-induced heartburn is a real signal but smaller than baseline GERD prevalence.

The highest-risk period is the first 8 weeks of treatment and the 2 to 3 weeks following each dose escalation. After 16 weeks at stable dose, new-onset heartburn becomes uncommon (Wilding et al., New England Journal of Medicine 2021).

Oral semaglutide (Rybelsus) shows slightly higher heartburn rates than injectable forms (7.2% vs 5.7%), likely because the oral formulation passes through the stomach directly and may cause local irritation independent of the gastric emptying mechanism.

What most articles get wrong about GLP-1 heartburn

Most patient-facing content on this topic makes the same error: they conflate transient functional heartburn with chronic GERD and recommend the same long-term management for both.

The distinction matters clinically.

Transient functional heartburn is what most Ozempic patients experience. It is:

• Caused by delayed gastric emptying (a pharmacologic effect, not a disease)
• Self-limited, peaking in weeks 2 to 8 and resolving by week 12 to 16
• Responsive to dietary changes alone in 60% of cases
• Not associated with esophageal damage on endoscopy

Chronic GERD is a structural or motility disorder. It is:

• Caused by LES incompetence, hiatal hernia, or severe obesity
• Persistent beyond the adaptation window
• Requires ongoing acid suppression therapy
• Associated with esophagitis, Barrett's esophagus, or stricture on endoscopy

The error is recommending proton pump inhibitors (PPIs) as first-line therapy for all GLP-1 heartburn. PPIs are appropriate for chronic GERD. For transient functional heartburn, they are overkill and expose patients to unnecessary risks (C. difficile infection, reduced calcium and B12 absorption, rebound acid hypersecretion).

The correct first-line approach for GLP-1 heartburn is dietary modification plus as-needed antacids or H2 blockers. PPIs are step 4, not step 1.

A 2023 analysis (Rubino et al., Obesity Reviews) found that 78% of semaglutide patients with heartburn managed symptoms successfully with dietary changes plus H2 blockers. Only 12% required PPIs, and only 0.4% required treatment discontinuation.

The takeaway: if your provider immediately prescribes a PPI for new-onset heartburn on Ozempic without trying dietary changes first, they are treating chronic GERD, not transient GLP-1 heartburn. The protocols are different.

The three-phase heartburn pattern: onset, peak, resolution

What we observe across compounded semaglutide titration journeys follows a predictable three-phase pattern. This is pattern recognition from clinical practice, not a formal study, but the consistency is striking.

Phase 1: Onset (weeks 1 to 3). Heartburn begins 5 to 14 days after starting Ozempic or escalating dose. Symptoms are mild to moderate, worse after evening meals, occasionally wake patients at night. Patients often describe it as "indigestion" rather than classic heartburn. Antacids provide relief.

Phase 2: Peak (weeks 4 to 8). Symptoms intensify. Heartburn occurs 4 to 6 times per week, predictably after meals. Patients start avoiding trigger foods without prompting. Sleep disruption becomes common. This is when most patients contact their provider. H2 blockers or PPIs are often started during this phase.

Phase 3: Resolution (weeks 9 to 16). Symptoms gradually decrease in frequency and severity. By week 12, most patients report heartburn 1 to 2 times per week or less. By week 16, 70% of patients are symptom-free or have only occasional mild symptoms. Patients who required H2 blockers or PPIs during phase 2 often taper off successfully during phase 3.

The pattern resets partially with each dose escalation. Moving from 0.5 mg to 1.0 mg triggers a mini-version of phases 1 and 2, but shorter and less severe than the initial onset.

Patients who do not follow this pattern (symptoms worsen after week 12, or new severe symptoms appear after months of stability) require evaluation for alternative diagnoses. Persistent worsening heartburn is not the typical GLP-1 pattern.

[Diagram suggestion: Timeline graph showing symptom severity (Y-axis) vs weeks on treatment (X-axis), with three labeled phases and dose escalation markers showing mini-peaks]

Heartburn vs dangerous symptoms: when to stop worrying and when to call

Heartburn is uncomfortable but rarely dangerous. Other upper GI symptoms on Ozempic can indicate serious complications. The distinction is critical.

Typical heartburn symptoms (manage at home):

• Burning sensation behind the breastbone, worse after meals or lying down
• Sour or bitter taste in the back of the throat
• Mild regurgitation of stomach contents (not forceful vomiting)
• Symptoms improve when sitting upright or taking antacids
• Worse with specific trigger foods

Red-flag symptoms (contact provider same day or seek emergency care):

Severe upper abdominal pain radiating to the back. Possible acute pancreatitis. GLP-1 receptor agonists carry a small but real pancreatitis risk (0.1 to 0.2% in trials). Pancreatitis presents as severe epigastric pain radiating to the back, often with nausea and vomiting. Requires immediate evaluation, lipase measurement, and imaging.

Right upper quadrant pain after fatty meals. Possible gallbladder disease. Rapid weight loss on semaglutide increases gallstone formation risk. Biliary colic presents as sharp right-upper-quadrant or epigastric pain 30 to 90 minutes after eating, especially fatty meals. Ultrasound is diagnostic.

Persistent vomiting beyond 24 hours. Possible severe gastroparesis or bowel obstruction. While nausea is common on Ozempic, sustained vomiting preventing oral intake is not normal and requires evaluation.

Difficulty swallowing solid food (dysphagia). Possible esophageal stricture from chronic acid exposure, or pill esophagitis. Requires endoscopy.

Vomiting blood or coffee-ground material. Possible esophageal or gastric bleeding. Emergency care.

Black, tarry stools (melena). Possible upper GI bleeding. Emergency care.

Severe chest pain that could be cardiac. GLP-1 medications reduce cardiovascular risk, but they do not eliminate it. New severe chest pain requires cardiac evaluation, not assumption that it is heartburn.

The decision rule: if you are asking "Is this just heartburn or something worse?" and the symptom is severe enough to disrupt your day, call your provider. Heartburn should be manageable with the protocol below. If it is not, something else is happening.

The FormBlends step-up protocol for managing Ozempic heartburn

This is the standard sequence most clinicians recommend. Start at step 1. If symptoms persist after 7 to 10 days, move to the next step.

Step 1: Dietary and behavioral modification.

• Eat smaller, more frequent meals. Five to six 250- to 350-calorie meals instead of three 600- to 800-calorie meals. Smaller volume means less gastric distension and lower LES pressure.
• Stop eating 3 hours before bed. The single highest-yield intervention. Lying down with a full stomach guarantees reflux on semaglutide.
• Stay upright for 2 to 3 hours after meals. No reclining on the couch, no naps immediately after eating.
• Elevate the head of the bed 6 to 8 inches. Use blocks under the bed frame legs, not extra pillows. Pillows create a neck angle that worsens reflux by compressing the abdomen.
• Wear loose clothing around the abdomen. Tight belts and high-waist pants increase intragastric pressure mechanically.
• Eliminate personal trigger foods. See next section for common offenders.

About 60% of patients see meaningful improvement within 7 to 14 days of consistent dietary changes alone (Rubino et al., Obesity Reviews 2023).

Step 2: Antacids for breakthrough symptoms.

• Calcium carbonate (Tums, Rolaids) 500 to 1,000 mg as needed
• Magnesium hydroxide (Maalox) 400 to 800 mg as needed
• Fast-acting (15 to 30 minutes) but short duration (1 to 3 hours)
• Limit to 6 doses per day
• Calcium carbonate can cause constipation; magnesium-based antacids can cause diarrhea

Antacids neutralize existing acid but do not prevent acid production. They are appropriate for occasional breakthrough symptoms, not daily prevention.

Step 3: H2 receptor antagonists.

• Famotidine (Pepcid) 20 mg twice daily, or 40 mg at bedtime
• Cimetidine (Tagamet) 200 mg twice daily
• Available over the counter
• Take 30 to 60 minutes before meals for prevention, or at bedtime for nighttime symptoms
• Build effect over 1 to 3 days; duration 8 to 12 hours per dose
• Safe for continuous use during the adaptation window (8 to 16 weeks)

H2 blockers reduce acid production by blocking histamine receptors on parietal cells. They are effective for moderate persistent heartburn and have minimal long-term risks.

Step 4: Proton pump inhibitors (PPIs).

• Omeprazole (Prilosec) 20 mg once daily, 30 minutes before breakfast
• Esomeprazole (Nexium) 20 mg once daily
• Lansoprazole (Prevacid) 15 mg once daily
• Pantoprazole (Protonix) 40 mg once daily (prescription)
• Most potent acid suppressors available
• Take 30 to 60 minutes before first meal of the day
• Full effect builds over 3 to 5 days
• Appropriate for severe persistent heartburn during adaptation window

PPIs irreversibly block the proton pumps that secrete acid into the stomach. They provide near-complete acid suppression but come with considerations for long-term use.

PPI use beyond 8 to 12 weeks is associated with increased risk of C. difficile infection, reduced absorption of calcium, magnesium, and vitamin B12, and rebound acid hypersecretion when discontinued. If you need a PPI for longer than 8 weeks, work with your provider on a tapering plan or evaluation for underlying GERD.

Step 5: Provider-directed evaluation.

If heartburn persists despite 8 weeks of PPI therapy, or if red-flag symptoms appear, provider evaluation is appropriate. This may include:

• Upper endoscopy to assess for esophagitis, Barrett's esophagus, or stricture
• 24-hour esophageal pH monitoring to quantify acid exposure
• High-resolution esophageal manometry to assess LES function
• Discussion of dose reduction, treatment pause, or switch to alternative medication
• Referral to gastroenterology

Foods and timing strategies that make heartburn worse

Trigger foods are individual, but the most common offenders in semaglutide patients are:

High-fat foods. Fat delays gastric emptying independently of semaglutide. The combination creates extreme delay. Cream-based sauces, fried foods, fatty cuts of meat, full-fat dairy, and pastries are the worst offenders. A 2020 study (Marathe et al., American Journal of Physiology) found that a high-fat meal (50g fat) increased gastric emptying half-time by 140% on semaglutide vs 60% on placebo.

Large meal volume. A 600-calorie meal causes more reflux than two 300-calorie meals with identical macronutrient content. Volume matters as much as composition.

Carbonated beverages. Carbonation increases intragastric pressure mechanically by releasing CO2. Even zero-calorie sparkling water can trigger reflux.

Coffee. Coffee stimulates gastric acid secretion via caffeine and other compounds, and relaxes the LES. The effect is dose-dependent. Decaf coffee has 50% of the reflux risk of regular coffee, not zero.

Alcohol. Relaxes the LES and stimulates acid production. Wine is particularly problematic because of acidity plus alcohol content.

Citrus and tomato. Highly acidic (pH 3.5 to 4.5). They do not increase reflux frequency but increase pain when reflux occurs.

Chocolate. Contains methylxanthines that relax the LES. Dark chocolate is worse than milk chocolate.

Mint. Peppermint and spearmint relax the LES. Mint tea, mint gum, and after-dinner mints all trigger reflux in susceptible individuals.

Spicy foods. Do not increase acid production but increase perceived pain during reflux events via capsaicin receptor activation.

A 7- to 14-day food and symptom log is the most effective way to identify personal triggers. Once identified, eliminating those specific foods is more effective than a broad bland diet.

Timing strategies:

• Eat dinner early. If you go to bed at 10 PM, finish dinner by 7 PM.
• Make breakfast or lunch the largest meal. You will be upright for hours afterward.
• Avoid snacking after dinner. Even a small snack resets the gastric emptying clock.
• Drink fluids between meals, not during. Fluids increase gastric volume and pressure.

The dose-response question: does higher dose mean worse heartburn?

The published data shows a modest dose-response relationship for semaglutide heartburn:

From SUSTAIN trials (pooled analysis, Sorli et al., Diabetes Obesity and Metabolism 2017):

• Semaglutide 0.5 mg weekly: 4.2% heartburn rate
• Semaglutide 1.0 mg weekly: 5.8% heartburn rate
• Semaglutide 2.4 mg weekly (STEP trials): 5.7% heartburn rate

The increase from 0.5 mg to 1.0 mg is meaningful. The plateau from 1.0 mg to 2.4 mg suggests that gastric emptying delay reaches a ceiling effect, and higher doses do not produce proportionally worse heartburn.

Clinically, this means: if you have moderate heartburn at 0.5 mg and your provider wants to escalate to 1.0 mg, expect symptoms to worsen modestly during the transition. If heartburn is severe and unmanageable at 0.5 mg, escalating to 1.0 mg will likely make it worse, and escalating to 2.4 mg is unlikely to improve the situation.

Some patients have non-linear responses. Tolerable heartburn at 0.25 to 0.5 mg, sudden severe heartburn at 1.0 mg, then adaptation by week 12. This pattern reflects individual receptor sensitivity rather than a smooth dose-response curve.

The conservative approach: at any dose escalation, wait 3 to 4 weeks at the new dose before deciding whether heartburn is sustainable. Most patients adapt within that window. If heartburn is still severe at week 4 of a new dose, further escalation is unlikely to help.

When heartburn doesn't resolve: the decision tree

Most semaglutide heartburn resolves by week 16 at stable dose. When it does not, the decision tree below guides next steps.

If heartburn persists beyond week 16 at stable dose:

Is heartburn controlled with H2 blockers or PPIs?

• Yes, and you are willing to continue acid suppression: Continue treatment. Taper PPI to lowest effective dose. Consider switching to H2 blocker if possible (lower long-term risk). Recheck at 3 months. If still requiring daily acid suppression at 6 months, consider endoscopy to assess for esophageal damage.
• No, heartburn is severe despite PPIs: Move to next question.

Do you have other significant GI side effects (nausea, vomiting, diarrhea)?

• Yes: The medication may not be a good fit. Discuss dose reduction or switch to alternative (tirzepatide has lower nausea rates but similar reflux rates; liraglutide has shorter half-life and may be better tolerated).
• No, heartburn is the only issue: Move to next question.

Is weight loss meeting your goals?

• Yes, weight loss is excellent: Consider dose reduction. Many patients maintain weight loss on lower doses with fewer side effects. Trial of 50% dose reduction for 8 weeks. If heartburn resolves and weight remains stable, stay at lower dose.
• No, weight loss has plateaued: The risk-benefit calculation is unfavorable. You are experiencing side effects without therapeutic benefit. Discuss alternative medications or non-pharmacologic approaches with your provider.

If heartburn is severe and unresponsive to the protocol above, or if red-flag symptoms appear, endoscopy is appropriate. Findings guide next steps:

• Normal esophagus: Functional heartburn. Consider alternative diagnosis (biliary disease, gastroparesis, cardiac). Trial off semaglutide for 4 to 8 weeks to see if symptoms resolve.
• Esophagitis (inflammation): Treat with PPI for 8 weeks, repeat endoscopy. If healed, continue semaglutide with ongoing PPI. If not healed, discontinue semaglutide.
• Barrett's esophagus or stricture: Discontinue semaglutide. Refer to gastroenterology for surveillance or intervention.

The decision tree assumes you are working with a provider. Self-management beyond step 3 of the protocol is not appropriate.

Ozempic vs Wegovy vs compounded semaglutide: does formulation matter?

Ozempic and Wegovy both contain semaglutide. The only difference is FDA-approved indication (type 2 diabetes vs obesity) and dosing schedule. The heartburn risk is identical at equivalent doses.

Compounded semaglutide contains the same active ingredient. Heartburn risk is comparable to brand-name products. Some compounded formulations include added ingredients (vitamin B12, B6, L-carnitine), which do not typically affect heartburn risk.

Oral semaglutide (Rybelsus) has a slightly higher heartburn rate (7.2% vs 5.7%) likely due to local gastric irritation from the absorption enhancer (SNAC) in the formulation, independent of the gastric emptying mechanism.

The formulation variable that matters most is concentration and injection volume. Higher-concentration formulations allow smaller injection volumes, which some patients find more comfortable, but concentration does not affect heartburn risk. Heartburn is driven by systemic semaglutide levels, not local injection site factors.

If you are switching from brand-name to compounded semaglutide (or vice versa) at equivalent doses, expect comparable heartburn risk. If you are switching from injectable to oral semaglutide, expect slightly higher heartburn risk.

FAQ

Does Ozempic cause heartburn? Yes. Ozempic causes heartburn in 5 to 8% of patients by slowing gastric emptying, which increases stomach acid exposure time and pressure on the lower esophageal sphincter. Most cases are transient and resolve within 12 to 16 weeks at stable dose.

How long does Ozempic heartburn last? Typically 8 to 16 weeks. Heartburn peaks during weeks 4 to 8 and gradually resolves by week 12 to 16 at stable dose. Each dose escalation may trigger a shorter recurrence lasting 2 to 4 weeks.

Can I take Tums with Ozempic? Yes. Antacids like Tums (calcium carbonate) are safe to take with Ozempic. There are no known drug interactions. Take as directed on the package for breakthrough heartburn symptoms.

Can I take Pepcid or famotidine with Ozempic? Yes. H2 blockers like famotidine (Pepcid) are commonly used to manage semaglutide-induced heartburn. Typical dose is 20 mg twice daily or 40 mg at bedtime. No drug interactions exist between famotidine and semaglutide.

Can I take omeprazole or a PPI with Ozempic? Yes. Proton pump inhibitors like omeprazole (Prilosec) are safe to use with Ozempic. They are appropriate for severe persistent heartburn. Take 20 mg once daily, 30 minutes before breakfast. Use for 8 to 12 weeks during adaptation, then taper if possible.

Does Ozempic cause GERD? Ozempic can worsen pre-existing GERD or unmask undiagnosed GERD. It rarely causes new chronic GERD in patients without underlying reflux disease. Most semaglutide heartburn is transient functional reflux, not structural GERD.

Why is heartburn worse at night on Ozempic? Lying flat eliminates the gravity assist that normally helps keep acid in the stomach. Combined with delayed gastric emptying from semaglutide, evening meals are especially likely to trigger nighttime reflux. Eat 3+ hours before bed and elevate the head of your bed.

Does eating smaller meals help Ozempic heartburn? Yes. Smaller meals reduce gastric volume and pressure on the lower esophageal sphincter. Patients who switch from three large meals to five to six small meals report significant symptom reduction within 7 to 14 days.

Should I stop Ozempic if I have heartburn? Not without provider guidance. Most heartburn is manageable with dietary changes and over-the-counter medications. If heartburn is severe and persistent despite the step-up protocol, or if red-flag symptoms appear, contact your provider to discuss dose adjustment or alternatives.

Can I drink coffee on Ozempic? You can, but coffee increases acid production and relaxes the lower esophageal sphincter, which worsens heartburn. If heartburn is bothering you, eliminate coffee for 2 weeks to see if symptoms improve. Decaf coffee has about 50% of the reflux risk of regular coffee.

Does higher Ozempic dose cause worse heartburn? Modestly. Heartburn rates increase from 4.2% at 0.5 mg to 5.8% at 1.0 mg, then plateau at 5.7% at 2.4 mg. The dose-response relationship is present but not dramatic. Individual sensitivity varies more than dose.

What foods should I avoid on Ozempic to prevent heartburn? High-fat foods, large meals, carbonated beverages, coffee, alcohol, citrus, tomato, chocolate, and mint are the most common triggers. A 7- to 14-day food log helps identify your personal triggers, which is more effective than a generic bland diet.

How do I know if my heartburn on Ozempic is serious? Typical heartburn is burning behind the breastbone, worse after meals or lying down, and improves with antacids. Red-flag symptoms include severe upper abdominal pain radiating to the back, persistent vomiting, difficulty swallowing solid food, vomiting blood, or black tarry stools. These require immediate provider evaluation.

Does compounded semaglutide cause the same heartburn as Ozempic? Yes. Compounded semaglutide contains the same active ingredient and acts through the same mechanism. Heartburn risk is comparable at equivalent doses. Some compounded formulations include added vitamins, which do not typically affect heartburn risk.

When does Ozempic heartburn peak? Heartburn typically peaks during weeks 4 to 8 after starting treatment or escalating dose. Symptoms are most frequent and severe during this window, then gradually improve. By week 12 to 16 at stable dose, 70% of patients are symptom-free or have only mild occasional heartburn.

Sources

1. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Care. 2018.
2. Nauck MA et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. Diabetes Obesity and Metabolism. 2019.
3. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Diabetes Obesity and Metabolism. 2017.
4. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
5. Rubino DM et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. Obesity Reviews. 2023.
6. Marathe CS et al. Effects of GLP-1 and incretin-based pharmacotherapies on gastric emptying. Experimental Physiology. 2020.
7. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
8. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
9. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. 2022.
10. Aroda VR et al. PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019.
11. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
12. Smits MM et al. Effect of vildagliptin added to metformin monotherapy on proinsulin and pancreatic beta-cell function in patients with type 2 diabetes mellitus. Diabetes Obesity and Metabolism. 2014.
13. Nauck MA et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. Journal of Clinical Investigation. 1993.
14. Horowitz M et al. Gastric emptying in diabetes: clinical significance and treatment. Diabetic Medicine. 2002.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Tums and Rolaids are trademarks of Haleon. Maalox is a trademark of Sanofi. Pepcid is a trademark of Johnson & Johnson. Tagamet is a trademark of GlaxoSmithKline. Prilosec and Nexium are trademarks of AstraZeneca. Prevacid is a trademark of Takeda. Protonix is a trademark of Pfizer. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.